Mersana Therapeutics, Inc.
http://www.mersana.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mersana Therapeutics, Inc.
GSK Makes ADC Pipeline Comeback With Mersana Deal
The UK major has teamed up with the US biotech to develop the latter’s HER-2 targeted antibody-drug conjugate, a couple of years after the approval of Blenrep, in what is becoming an increasingly competitive space.
Financing Quarterly Statistics, Q2 2022
During Q2, biopharmas brought in an aggregate $12.5bn in financing and device company fundraising totaled $3.7bn; while in vitro diagnostic firms and research tools players raised $720m.
Finance Watch: VC Fundraising Dips In Q2, But Mega-Deal Pace Is Strong
Private Company Edition: The amount of venture capital raised by biopharma firms fell but individual companies grabbed a lot of cash, making for a remarkable Q2 relative to pre-pandemic times. Recent Q3 rounds includes Frontera’s $160m series B. Also, Oxford Science Enterprises added €250m to its fund.
Science Matters: Harnessing The Inherent Power Of MAIT Cells
Tapping into the interplay between gut microbiota and an underappreciated subset of T cells could lead to therapies in a range of diseases.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Nanotechnology, Chips, etc.
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Nanopharma Corp.